Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nordic Nanovector ASA: Invitation to Third Quarter 2021 Results Presentation and Webcast

Oslo, Norway, 12 November 2021 Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the third quarter 2021 on Thursday, 18 November 2021. A presentation by Nordic Nanovector’s senior management team will be held in-person and webcast live beginning at 8:30am CET. Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: Bjørvika The webcast can be accessed from www.nordicnanovector.com 

Mainstream Renewable Power Secures Investment Decision from Provincial Government for Flagship Offshore Wind Project in Vietnam

· The 1.4 GW Phu Cuong Soc Trang offshore wind project, being developed as a joint venture between Mainstream Renewable Power and the Phu Cuong Group, is located off the southern coast of Vietnam and will be the largest offshore wind farm in South-East Asia · The first 200 MW of the project has received a Decision on Investment and an Investment Registration Certificate (IRC) from the Soc Trang Province, representing a significant step towards financial close, expected in 2022In a vital step for the Phu Cuong Soc Trang Offshore Wind Farm, Mainstream Renewable Power (“Mainstream”) today

Invitation to presentation of Storskogen’s interim report for the third quarter 2021

On 18 November 2021 at 07:00 CET, Storskogen announces its interim report for the third quarter 2021. In connection with the announcement, a webcast with a subsequent Q&A session will be held by Daniel Kaplan, CEO, and Lena Glader, CFO. The presentation will be held in english.The webcast starts at 09:00 CET on 18 November 2021. It will be possible to ask questions verbally in the webcast. Questions can also be sent to ir@storskogen.com. To participate in the webcast and to ask questions, please use the following link and follow the instructions: https://live.twebcast.com/participant/

“Life science means everything”

Never miss a routine check-up, examine your breasts monthly, and if something feels off – don’t linger. Go see a doctor. These are the top pieces of advice from Getinge’s Linda Skogsberg who had to put her hopes to life science while going through breast cancer. Something in the results from Linda Skogsberg’s mammography was unclear, and she was called for a second screening. “Those days are like a haze to me. I was worried and couldn’t focus on anything else but waiting to hear back from the hospital. When they called and asked me to come in the next day and bring a relative I

Nanoform receives ISO/IEC 27001:2013 certification for its Information Security Management System

Press release Nanoform Finland Plc November 12, 2021 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Nanoform receives ISO/IEC 27001:2013 certification for its Information Security Management System Helsinki, Finland - Nanoform, an innovative nanoparticle medicine enabling company, today announced it has received ISO/IEC 27001:2013 certification for its Information Security Management System (ISMS). The ISMS applies to all information, systems, processes, and people that operate, store, handle, and process Nanoform’s and its clients’ trusted data. It covers the IT services

Aker ASA: Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Aker ASA’s shares

November 12, 2021 – Kristin Krohn Devold, director in Aker ASA, has today acquired 590 shares in Aker ASA at a price of NOK 877.23 per share. The shares were acquired on the Oslo Stock Exchange. Following the transaction, Devold holds a total of 590 shares in Aker ASA. Please see attached notification for persons discharging managerial responsibilities in Aker ASA in accordance with Regulation EU 596/2014 (MAR) article 19 and section 5-12 of the Norwegian Securities Trading Act. -ENDS- For more information, please contact: Investors:Joachim Bjørni, Head of Investor Relations,

Tikkurila Colour of the Year 2022: Every adventure begins at home

Tikkurila’s colour of the year is L478 Kestrel, calm and grounding brown with a hint of cool red. It borrows its name from a Kestrel, a falcon species that’s torn between two homes.Much like Kestrels’, our homes are not static. Our homes are built upon our memories and experiences that we draw inspiration from. Wherever we go becomes a part of us and our home. This grounding colour will offer a warm feeling of familiarity with interesting undertones that makes a home feel elegant in an inviting way. “In the past two years, we’ve been paying more attention to our spaces, but we’ve also

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 85 - 12 NOVEMBER 2021 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 75/2021. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tlf.: 3315 0451

Dentalum acquires Tandläkarhuset Enköping

Dentalum expands through the acquisition of Tandläkarhuset Enköping. The group thereby consists of 21 clinics in eight regions in Sweden.On February 1, 2022, Dentalum will enter its partnership with Ehsan and Ashkan Ahari and their team at Tandläkarhuset Enköping. The clinic was founded in 2013 by Ehsan Ahari and is centrally located in Enköping with six treatment rooms. The clinic currently offers general dental care, implant treatments and various aesthetic treatments such as teeth whitening and orthodontics with Invisalign. · We were contacted by Dentalum about a year ago and had

BioStock: BiBBInstruments continues to lay groundwork for commercialisation

With the release of the Q3 report, Swedish medtech BibbInstruments continues to make the case that it has what it takes to make an impact on the fast-growing endoscopic ultrasound market. With two ongoing pilot clinical trials on their way towards finalisation with the core biopsy instrument EndoDrill Model X, the cancer diagnostics company has been diligent in preparing the regulatory framework necessary for potential commercialisation in both Europe and the US once clinical evaluation is complete.Read the article at biostock.se : https://www.biostock.se/en/

Notice of Extra General Meeting in Storytel AB (publ)

The shareholders of Storytel AB (publ), reg. no. 556575-2960, (the "Company"), are hereby convened to the extra general meeting to be held on Tuesday 30 November 2021.   Information with respect to the coronavirus   The Company is mindful of the health and well-being of its shareholders and employees. It´s important for the Company to take a social responsibility and contribute to reduce the risk of transmission of the Covid-19. Due to the extraordinary situation the extra general meeting will be carried out through advance voting (postal voting) pursuant to temporary

Storytel to acquire streaming service Audiobooks.com – entering the U.S. market

The Storytel Group (“Storytel”), one of the world’s largest audiobook and e-book streaming companies, has signed a definitive agreement to acquire Audiobooks.com from KKR. Audiobooks.com is one of the leading services for audiobook experiences in the U.S. With this acquisition, Storytel extends its trajectory of expansion and profitable growth to the largest English-language audio market in the world.Since launching in 2011, Audiobooks.com has cultivated a strong brand presence in the U.S. audiobook market. With a focus on user experience in top-rated apps for iOS and Android devices,

BioStock: BioInvent’s CMO on new positive data with BI-1206

BioInvent has presented additional positive interim data from the company’s phase I/IIa clinical trial with drug candidate BI-1206 for immunotherapy treatment in patients with non-Hodgkin’s lymphoma. Biostock reached out to the company’s Chief Medical Officer, Andres McAllister, who is excited about seeing clinical responses this early in the trial. He is also very impressed by the quality and long duration of the responses.Read the full interview with Andres McAllister at biostock.se: https://www.biostock.se/en/2021/11/bioinvents-cmo-on-new-positive-data-with-bi-1206/ This is a press

BioStock: Toleranzia advances its projects despite challenges linked to Covid-19

Toleranzia, that develops potentially curative treatments for severe autoimmune diseases, is, like many other companies, affected by the Covid-19 pandemic. The company recently announced that the planned clinical trial of its drug candidate TOL2 will be postponed until the second half of 2023, due to the fact that the unabated global need for Covid-19 vaccine in the world is causing an extensive shortage of materials needed to purify Toleranzia’s drug candidate. BioStock contacted Toleranzia’s CEO Charlotte Fribert to find out how the company is affected by the delay.Read the full interview

Bonava acquires approximately 370 building rights in Umeå

Bonava has signed an agreement to acquire approximately 370 building rights for multi-family housing in Umeå from Motorcentralen. The final purchase price is based on the planned area for housing units and will be paid in conjunction with the zoning plan entering force, on a preliminary basis, in late 2023. The start of construction is planned for 2024.– Bonava has a strong position in Umeå and positive experiences of operating in the municipality. This large land acquisition is in a very attractive location and further strengthens our position, says Fredrik Hemborg, Business Unit President,

Swedbank Robur lowers fees on 10 funds

At the end of October, Swedbank Robur adopted the decision to reduce the fee of 10 of their funds, which involves a fee reduction for the funds of between 0.1- 0.3 percentage points. The reduction is a result of the continuous work to review and ensure a relevant and attractive product offering, as well as further aligning the product offer with the fund company's business strategy which platform is based on simplicity, innovation and sustainability.The purpose of the fee reduction is to ensure an attractive offer to savers and to continue building on a transparent, logical, and easy to

Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 2021

Poster presentation to highlight the ability of ATOR-1017 to activate and rescue tumor infiltrating exhausted T cells in synergy with PD-1Lund, Sweden, November 12, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced new preclinical data highlighting the 4-1BB (CD137) antibody ATOR-1017 including an update on the ongoing phase 1 study. ATOR-1017, a promising candidate for immunotherapy with enormous potential for combination with other immunomodulatory antibodies, will be presented at the Society for Immunotherapy Cancer’s (SITC) 36[th] Annual Meeting & Pre-

Alligator Announces Poster Presentation on Neo-X-Prime™ presenting data on the lead compound targeting CD40 and CEA at SITC Virtual Annual Meeting 2021

Poster Presentation to highlight our Neo-X-Prime™ platform that aims to enable antigen presenting cells to efficiently enhance priming of tumor neoantigen-specific T cells with the goal of overcoming PD-1 resistance in certain tumor typesLund, Sweden, November 12, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that data highlighting the efficacy and safety of Neo-X-Prime™ bsAbs and how Alligator’s lead compound targeting CD40 and CEA meets key needs in Immuno-oncology, will be presented at the Society for Immunotherapy Cancer’s (SITC) 36[th] Annual Meeting &

OKEA acquires 2.223% in the Ivar Aasen field from Neptune Energy

(Trondheim, 12 November 2021) OKEA ASA (OSE: OKEA) today announces the purchase of 2.223% working interest (WI) in the Ivar Aasen field from Neptune Energy Norge AS (“Neptune”). Total compensation is up to USD 12.7 million dependent on the oil price in 2022. The acquisition will add to OKEA’s current holding of 0.554% WI in Ivar Aasen and increases the ownership share to 2.777% following the transaction. The effective date of the transaction is 1 January 2022.  OKEA’s acquisition of the Ivar Aasen stake is a part of a larger transaction involving M Vest Energy AS (“M Vest”).  In total,

Invitation to presentation of Thunderful Group’s interim report Q3 2021

Thunderful Group invites to a teleconference/audiocast November 16, 2021, 10.30 CET.The interim report for q3 2021 is presented and thereafter there is an opportunity to ask questions. Questions can be posed verbally via the teleconference, or in writing via the audiocast. A recorded version of the presentation will also be available on Thunderful Group's website. The presentation will be held in English. The interim report is published at 07.30 CET November 16, 2021. Present:Brjann Sigurgeirsson, CEOAnders Maiqvist, CFO The teleconference will be available at:SE: +46850558374

Oncopeptides has announced the Nomination Committee

STOCKHOLM — November 12, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2022 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30, along with the Chairman of the Board of Directors.The composition of the Nomination Committee has now been established, and Oncopeptides today announced that the Nomination Committee in respect of the annual general meeting 2022

BioStock: Promising study results for Invent Medic

Urine leakage is a common problem that limits many women’s lives while at the same time being a taboo subject to discuss. Lund-based Invent Medic has developed the Efemia bladder support to reduce worry about Stress Urinary Incontinence. A study testing Efemia in women who experience leakage while running recently presented promising results. BioStock contacted Klara Rasmusson, Customer Success Manager at the company, to find out more.Read the full article at biostock.se:https://www.biostock.se/en/2021/11/promising-study-results-for-invent-medic/This is a press release from BioStock -

PowerCell Sweden AB brings forward the publication of the report for the fourth quarter 2021

PowerCell Sweden AB (publ) has decided to bring forward the publication of the report for the fourth quarter 2021 to 11 February 2022 at 08.30 a.m. CET. The previously announced date for publication was 17 February.For further information, please contact: Richard BerklingCEO, PowerCell Sweden AB (publ)Phone: +46 (0) 31 720 36 20Email: richard.berkling@powercell.se About PowerCell Sweden AB (publ) PowerCell Sweden AB (publ) develops and produces fuel cell stacks and systems for stationary and mobile applications with a world class energy density. The fuel cells are powered by

Interim Report January-September 2021

Deliveries have started, and ChromoGenics improved its earningsThird quarter of 2021 · ChromoGenics began in-house production of its dynamic glass ConverLight® Dynamic at the end of May at a slow rate to reduce the risk of production disruptions. During the quarter, the rate of production was gradually increased with several deliveries to our customers. · After ChromoGenics completed the long-term tests of the in-house dynamic glass ConverLight[® ]Dynamic in mid-June, the top priority has been the post-inspection. Our focus is now on increasing the rate of production step by step in

There are no items matching the current filter
There are no more items matching the current filter
Back to top